SS
VKTX icon

SBI Securities’s Viking Therapeutics VKTX Stock Holding History

SBI Securities’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Sell
28,729
-2,886
-9% -$93.2K 0.03% 270
2026
Q1 		$1.03M Buy
31,615
+14,511
+85% +$466K 0.03% 270
2025
Q4 		$602K Sell
17,104
-6,509
-28% -$231K 0.02% 356
2025
Q3 		$621K Buy
23,613
+20,775
+732% +$620K 0.02% 347
2025
Q2 		$75.2K Sell
2,838
-173
-6% -$4.55K ﹤0.01% 910
2025
Q1 		$72.7K Buy
3,011
+105
+4% +$3.32K ﹤0.01% 847
2024
Q4 		$117K Buy
+2,906
New +$166K ﹤0.01% 711

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

SBI Securities's VKTX Position: Q2 2026 in Review

SBI Securities reduced its Viking Therapeutics (VKTX) stake by 9.1% in Q2 2026, selling an estimated $93.2K and leaving 28,729 shares worth $1.12M. The position accounts for 0.03% of the portfolio, ranked #270.

SBI Securities first reported a position in VKTX in Q4 2024 and has held it in 7 quarters since. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • SBI Securities held 28,729 shares of Viking Therapeutics worth $1.12M as of Q2 2026.
  • SBI Securities sold 2,886 Viking Therapeutics shares in Q2 2026, an estimated $93.2K.
  • Viking Therapeutics made up 0.03% of SBI Securities's portfolio in Q2 2026, its #270 holding.
  • SBI Securities first reported a position in Viking Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.